| Literature DB >> 22878820 |
Margaret von Mehren1, Robert S Benjamin, Marilyn M Bui, Ephraim S Casper, Ernest U Conrad, Thomas F DeLaney, Kristen N Ganjoo, Suzanne George, Ricardo Gonzalez, Martin J Heslin, John M Kane, Joel Mayerson, Sean V McGarry, Christian Meyer, Richard J O'Donnell, Benjamin Paz, John D Pfeifer, Raphael E Pollock, R Lor Randall, Richard F Riedel, Scott Schuetze, Karen D Schupak, Herbert S Schwartz, Sridhar Shankar, Brian A Van Tine, Jeffrey Wayne, Hema Sundar, Nicole R McMillian.
Abstract
The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors (GISTs) and desmoid tumors (aggressive fibromatosis). Postoperative imatinib following complete resection for primary GIST with no preoperative imatinib is now included as a category 1 recommendation for patients with intermediate or high risk of recurrence. The panel also reaffirmed the recommendation for preoperative use of imatinib in patients with GISTs that are resectable with negative margins but associated with significant surgical morbidity. Observation was included as an option for patients with resectable desmoid tumors that are small and asymptomatic, not causing morbidity, pain, or functional limitation. Sorafenib is included as an option for systemic therapy for patients with desmoid tumors.Entities:
Mesh：
Year: 2012 PMID： 22878820 DOI： 10.6004/jnccn.2012.0099
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908